Patients on trilaciclib received more chemotherapy cycles than those in the control arm Trilaciclib showed multi-lineage myelopreservation benefits when adjusting for longer duration of treatment Safety profile consistent with previously reported trials; no trilaciclib-related serious adverse
Second randomized, double-blind, placebo-controlled Phase 2 trial confirms multi-lineage myelopreservation benefits of trilaciclib in first-line small cell lung cancer (1L SCLC) Statistically significant improvements in both primary endpoints of occurrence of Grade 4 neutropenia and duration of
RESEARCH TRIANGLE PARK, N.C. , Nov. 09, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that preliminary data from its randomized Phase 2 clinical trial of trilaciclib in combination with chemotherapy for the treatment of metastatic
Positive data from randomized Phase 2 trilaciclib/chemotherapy trial in first-line small cell lung cancer presented at ESMO 2018 highlight myelopreservation and immune system benefits of trilaciclib Preliminary data from three additional randomized Phase 2 clinical trials of trilaciclib expected by
RESEARCH TRIANGLE PARK, N.C. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca , M.D., Ph.D., will provide a company overview at the following upcoming investor conferences in
RESEARCH TRIANGLE PARK, N.C. , Oct. 30, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call to provide a corporate and financial update for the third quarter of 2018 on Wednesday, November
New data analyses highlight myelopreservation and immune system benefits of trilaciclib in combination with chemotherapy Data presented at the European Society for Medical Oncology ( ESMO ) 2018 Congress RESEARCH TRIANGLE PARK, N.C. , Oct. 21, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc.
New data analyses demonstrate multi-lineage benefits of trilaciclib on neutrophils, red blood cells and lymphocytes in treatment of first-line small cell lung cancer RESEARCH TRIANGLE PARK, N.C. , Oct. 09, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc.
RESEARCH TRIANGLE PARK, N.C. , Sept. 21, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced the closing of an underwritten public offering of 3,450,000 shares of its common stock at a public offering price of $60.00 per share, including
RESEARCH TRIANGLE PARK, N.C. , Sept. 18, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $60.00 per share, for total
RESEARCH TRIANGLE PARK, N.C. , Sept. 17, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it has commenced an underwritten public offering of 3,000,000 shares of its common stock. All of the shares in the offering will be sold by
Management to host webcast and conference call today at 8:30 a.m. ET RESEARCH TRIANGLE PARK, N.C. , Sept. 17, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it is expediting analyses of myelopreservation data from its
RESEARCH TRIANGLE PARK, N.C. , Sept. 13, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Garry Nicholson has been appointed to its board of directors, effective September 12, 2018 . “We are pleased to welcome Garry as an
RESEARCH TRIANGLE PARK, N.C. , Aug. 28, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Buck Phillips , Chief Financial Officer and Senior Vice President, Corporate Development will present a company overview at the following
Presenting additional data from randomized Phase 2 trilaciclib/chemotherapy trial in first-line small cell lung cancer at ESMO 2018 in October Initiated Phase 2a enrollment of lerociclib (G1T38) in ER+, HER2- breast cancer; positive Phase 1b data presented at ASCO 2018 Management to host
RESEARCH TRIANGLE PARK, N.C. , Aug. 07, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Medical Officer Raj Malik, M.D., will present a company overview at the following investor conference: Wedbush PacGrow Healthcare
RESEARCH TRIANGLE PARK, N.C. , Aug. 01, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call to provide a corporate and financial update for the second quarter of 2018 on Wednesday, August
RESEARCH TRIANGLE PARK, N.C. , July 09, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced appointments for two newly created executive leadership roles to support the company’s continued growth.
RESEARCH TRIANGLE PARK, N.C. , June 08, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that Cynthia Schwalm and Willie Deese have been appointed to its board of directors, effective June 7, 2018 .
RESEARCH TRIANGLE PARK, N.C. , June 02, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that preliminary data from its Phase 1b/2a clinical trial of G1T38 in combination with Faslodex ® (fulvestrant) showed promising safety,
RESEARCH TRIANGLE PARK, N.C. , May 16, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that preliminary data from its Phase 1b/2a clinical trial of G1T38 in combination with Faslodex ® (fulvestrant) will be presented in a poster
U.S. and European regulatory meetings scheduled based on positive trilaciclib Phase 2a myelopreservation data Preliminary data from G1T38 Phase 1b trial in breast cancer to be presented at ASCO on June 2 Management to host webcast and conference call today at 4:30 p.m.
RESEARCH TRIANGLE PARK, N.C. , May 01, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca , M.D., Ph.D., will present a company overview at the following investor conference: UBS Global
RESEARCH TRIANGLE PARK, N.C. , April 26, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced it will host a webcast and conference call to provide a corporate and financial update for the first quarter of 2018 on Thursday, May 3 at 4:30
RESEARCH TRIANGLE PARK, N.C. , April 16, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that it has initiated a Phase 1b/2 clinical trial assessing G1T38, its oral CDK4/6 inhibitor, in combination with Tagrisso ® (osimertinib) in
RESEARCH TRIANGLE PARK, N.C. , April 09, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that preclinical data on both of the company’s CDK4/6 inhibitors will be presented at the 2018 American Association for Cancer Research Annual
RESEARCH TRIANGLE PARK, N.C. , March 12, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced the closing of an underwritten public offering of 3,910,000 shares of its common stock at a public offering price of $29.50 , including 510,000
RESEARCH TRIANGLE PARK, N.C. , March 07, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced the pricing of an underwritten public offering of 3,400,000 shares of its common stock at a public offering price of $29.50 , for total gross
RESEARCH TRIANGLE PARK, N.C. , March 05, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that it has commenced an underwritten public offering of 3,000,000 shares of its common stock. All of the shares in the offering will be sold by
Statistically significant results highlight benefit of trilaciclib in several prospectively-defined parameters, including: Grade 4 neutropenia, G-CSF usage, and chemotherapy dose reductions and delays Clinically meaningful data favoring trilaciclib versus placebo, including: febrile neutropenia,
RESEARCH TRIANGLE PARK, N.C. , March 01, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca , M.D., Ph.D., will present a company overview at the following upcoming investor conferences in March:
Topline data expected in March 2018 from first of three ongoing Phase 2 trials evaluating the myelopreservation benefits of trilaciclib Management to host webcast and conference call today at 4:30 p.m. EST RESEARCH TRIANGLE PARK, N.C. , Feb. 21, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc.
RESEARCH TRIANGLE PARK, N.C. , Feb. 14, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that fourth quarter and full-year 2017 financial results will be reported on Wednesday, February 21, 2018 , after the close of U.S.
RESEARCH TRIANGLE PARK, N.C. , Jan. 02, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca , M.D., Ph.D., will present a company overview at the 36th Annual J.P. Morgan Healthcare Conference .
